Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Apr 29;6(5):e0714.
doi: 10.1097/HS9.0000000000000714. eCollection 2022 May.

The EHA Research Roadmap: Hematopoietic Stem Cells and Allotransplantation

Willem Fibbe  1 , Rosa Bernardi  2 , Pierre Charbord  3 , Daniela Krause  4 , Cristina Lo Celso  5 , Simón Méndez-Ferrer  6 , Christine Mummery  7 , Robert Oostendorp  8 , Marc Raaijmakers  9 , Gerard Socié  10 , Frank Staal  11 , Andrea Bacigalupo  12
Affiliations
Editorial

The EHA Research Roadmap: Hematopoietic Stem Cells and Allotransplantation

Willem Fibbe et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Induced pluripotent stem cells: the new patient? Permission for reuse obtained from Nature/Springer.
See this image and copyright information in PMC

References

    1. Engert A, Balduini C, Brand A, et al. . The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica. 2016;101:115–208. - PMC - PubMed
    1. de Lima M, Porter DL, Battiwalla M, et al. . Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and treatment of relapse after hematopoietic stem cell transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant. 2014;20:4–13. - PMC - PubMed
    1. Falkenburg F, Ruggiero E, Bonini C, et al. . Prevention and treatment of relapse after stem cell transplantation by cellular therapies. Bone Marrow Transplant. 2019;54:26–34. - PubMed
    1. Lovisa F, Zecca M, Rossi B, et al. . Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. Br J Haematol. 2018;180:680–693. - PubMed
    1. Cho BS, Min GJ, Park SS, et al. . WT1 measurable residual disease assay in patients with acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation: optimal time points, thresholds, and candidates. Biol Blood Marrow Transplant. 2019;25:1925–1932. - PubMed

Publication types